Search Results - "Lapteva, Natalia"

Allogeneic, off-the-shelf, SARS-CoV-2-specific T cells (ALVR109) for the treatment of COVID-19 in high-risk patients by Vasileiou, Spyridoula, Hill, LaQuisa, Kuvalekar, Manik, Workineh, Aster G, Watanabe, Ayumi, Velazquez, Yovana, Lulla, Suhasini, Mooney, Kimberly, Lapteva, Natalia, Grilley, Bambi J, Heslop, Helen E, Rooney, Cliona M, Brenner, Malcolm K, Eagar, Todd N, Carrum, George, Grimes, Kevin A, Leen, Ann M, Lulla, Premal

“…Defects in T-cell immunity to SARS-CoV-2 have been linked to an increased risk of severe COVID-19 (even after vaccination), persistent viral shedding and the…”
Get full text

Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients by Szmania, Susann, Lapteva, Natalia, Garg, Tarun, Greenway, Amy, Lingo, Joshuah, Nair, Bijay, Stone, Katie, Woods, Emily, Khan, Junaid, Stivers, Justin, Panozzo, Susan, Campana, Dario, Bellamy, William T, Robbins, Molly, Epstein, Joshua, Yaccoby, Shmuel, Waheed, Sarah, Gee, Adrian, Cottler-Fox, Michele, Rooney, Cliona, Barlogie, Bart, van Rhee, Frits

“…Highly activated/expanded natural killer (NK) cells can be generated by stimulation with the human leukocyte antigen-deficient cell line K562, genetically…”
Get full text

Comprehensive Approach for Identifying the T Cell Subset Origin of CD3 and CD28 Antibody-Activated Chimeric Antigen Receptor-Modified T Cells by Schmueck-Henneresse, Michael, Omer, Bilal, Shum, Thomas, Tashiro, Haruko, Mamonkin, Maksim, Lapteva, Natalia, Sharma, Sandhya, Rollins, Lisa, Dotti, Gianpietro, Reinke, Petra, Volk, Hans-Dieter, Rooney, Cliona M

“…The outcome of therapy with chimeric Ag receptor (CAR)-modified T cells is strongly influenced by the subset origin of the infused T cells. However, because…”
Get full text

Enhanced migration of human dendritic cells expressing inducible CD40 by Lapteva, Natalia

“…Dendritic cells (DC) are the most potent antigen-presenting cells for priming and activating naïve CD4(+) and CD8(+) T lymphocytes. This property has led to…”
Get more information

Multi-antigen-targeted T-cell therapy to treat patients with relapsed/refractory breast cancer by Hoyos, Valentina, Vasileiou, Spyridoula, Kuvalekar, Manik, Watanabe, Ayumi, Tzannou, Ifigeneia, Velazquez, Yovana, French-Kim, Matthew, Leung, Wingchi, Lulla, Suhasini, Robertson, Catherine, Foreman, Claudette, Wang, Tao, Bulsara, Shaun, Lapteva, Natalia, Grilley, Bambi, Ellis, Matthew, Osborne, Charles Kent, Coscio, Angela, Nangia, Julie, Heslop, Helen E., Rooney, Cliona M., Vera, Juan F., Lulla, Premal, Rimawi, Mothaffar, Leen, Ann M.

“…Purpose: Adoptively transferred, ex vivo expanded multi-antigen-targeted T cells (multiTAA-T) represent a new, potentially effective, and nontoxic therapeutic…”
Get full text

A composite MyD88/CD40 switch synergistically activates mouse and human dendritic cells for enhanced antitumor efficacy by Narayanan, Priyadharshini, Lapteva, Natalia, Seethammagari, Mamatha, Levitt, Jonathan M, Slawin, Kevin M, Spencer, David M

“…The in vivo therapeutic efficacy of DC-based cancer vaccines is limited by suboptimal DC maturation protocols. Although delivery of TLR adjuvants systemically…”
Get full text

The phosphatase SRC homology region 2 domain-containing phosphatase-1 is an intrinsic central regulator of dendritic cell function by Ramachandran, Indu R, Song, Weitao, Lapteva, Natalia, Seethammagari, Mamatha, Slawin, Kevin M, Spencer, David M, Levitt, Jonathan M

“…Dendritic cells (DCs) initiate proinflammatory or regulatory T cell responses, depending on their activation state. Despite extensive knowledge of…”
Get full text

Enhanced Activation of Human Dendritic Cells by Inducible CD40 and Toll-like Receptor-4 Ligation by LAPTEVA, Natalia, SEETHAMMAGARI, Mamatha R, HANKS, Brent A, JIANGHONG JIANG, LEVITT, Jonathan M, SLAWIN, Kevin M, SPENCER, David M

“…Despite the potency of dendritic cells (DC) as antigen-presenting cells for priming adaptive immunity, DC-based cancer vaccines have been largely insufficient…”
Get full text

Chimeric Antigen Receptor Signaling Domains Differentially Regulate Proliferation and Native T Cell Receptor Function in Virus-Specific T Cells by Omer, Bilal, Castillo, Paul A, Tashiro, Haruko, Shum, Thomas, Huynh, Mai T A, Cardenas, Mara, Tanaka, Miyuki, Lewis, Andrew, Sauer, Tim, Parihar, Robin, Lapteva, Natalia, Schmueck-Henneresse, Michael, Mukherjee, Malini, Gottschalk, Stephen, Rooney, Cliona M

“…The efficacy of T cells expressing chimeric antigen receptors (CARs) for solid tumors has been limited by insufficient CAR T cell expansion and persistence…”
Get full text

Optimization Manufacture of Virus- and Tumor-Specific T Cells by Lapteva, Natalia, Vera, Juan F.

“…Although ex vivo expanded T cells are currently widely used in pre-clinical and clinical trials, the complexity of manufacture remains a major impediment for…”
Get full text

Activation and suppression of renin–angiotensin system in human dendritic cells by Lapteva, Natalia, Ide, Kazuki, Nieda, Mie, Ando, Yoshitaka, Hatta-Ohashi, Yoko, Minami, Mutsuhiko, Dymshits, Grigory, Egawa, Koichi, Juji, Takeo, Tokunaga, Katsushi

“…We previously identified the gene expression of renin–angiotensin system in human monocyte-derived dendritic cells (DCs). This study was conducted to examine…”
Get full text

NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors by Parihar, Robin, Rivas, Charlotte, Huynh, Mai, Omer, Bilal, Lapteva, Natalia, Metelitsa, Leonid S, Gottschalk, Stephen M, Rooney, Cliona M

“…Solid tumors are refractory to cellular immunotherapies in part because they contain suppressive immune effectors such as myeloid-derived suppressor cells…”
Get more information

N-acetyltransferase 2 (NAT2) Gene Polymorphisms and the Effectiveness of Infertility Treatment in Patients with Peritoneal Endometriosis by Ekaterina D. Dubinskaya, Alexander S. Gasparov, Tatyana A. Fedorova, Natalia V. Lapteva

“…Today, infertility has become a global issue. WHO ranks it the fifth among the major diseases of those below 60 years, after alcoholism, depression, injuries…”
Get full text

Phase 1 clinical trial of adoptive immunotherapy using “off-the-shelf” activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia by Boyiadzis, Michael, Agha, Mounzer, Redner, Robert L., Sehgal, Alison, Im, Annie, Hou, Jing-Zhou, Farah, Rafic, Dorritie, Kathleen A., Raptis, Anastasios, Lim, Seah H., Wang, Hong, Lapteva, Natalia, Mei, Zhuyong, Butterfield, Lisa H., Rooney, Cliona M., Whiteside, Theresa L.

“…Activated NK cells (aNK) generated by expansion of a human interleukin-2–dependent NK cell line (NK-92) were shown to mediate strong anti-leukemia activity…”
Get full text

An Optimized Process of Generating CAR-T Cells for Clinical Applications by Bajgain, Pradip, Mucharla, Roopa, Wilson, John, Lapteva, Natalia, PhD, Heslop, Helen E., MD, Rooney, Cliona M., PhD, Brenner, Malcolm K., MD, PhD, Leen, Ann M., PhD, Vera, Juan F., MD

Get full text

Establishment of a Highly Characterized Third-Party Virus-Specific T Lymphocyte Bank for Treatment of EBV+ Lymphoma by Rouce, Rayne Helen, M.D, Thakkar, Aarohi, Vyas, Gayatri, Sharma, Sandhya, Perna, Serena K., M.D, Ramos, Carlos A., MD, Lapteva, Natalia, PhD, Reyna, Amy, Leen, Ann M., PhD, Heslop, Helen E., MD, Rooney, Cliona M., PhD

Get full text

Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas by Hill, LaQuisa C., Rouce, Rayne H., Wu, Mengfen J., Wang, Tao, Ma, Royce, Zhang, Huimin, Mehta, Birju, Lapteva, Natalia, Mei, Zhuyong, Smith, Tyler S., Yang, Lina, Srinivasan, Madhuwanti, Burkhardt, Phillip M., Ramos, Carlos A., Lulla, Premal, Arredondo, Martha, Grilley, Bambi, Heslop, Helen E., Brenner, Malcolm K., Mamonkin, Maksim

“…•Autologous CD5 CAR T cells induce clinical responses in r/r mature TCLs.•CD5 CAR T cells were associated with low-grade cytokine release syndrome and…”
Get full text

Safety and Efficacy Profile of Autologous CD30.CAR-T-Cell Therapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (CHARIOT Trial) by Ahmed, Sairah, Flinn, Ian W., Mei, Matthew, Riedell, Peter A., Armand, Philippe, Grover, Natalie S, Engert, Andreas, Lapteva, Natalia, Nadler, Paul I., Myo, Aung, Heslop, Helen E.

“…Introduction CD19-targeting chimeric antigen receptor (CAR) T-cell therapy has been transformative in B-cell lymphoid malignancies. CD30 is a validated target…”
Get full text

CCL5 as an adjuvant for cancer immunotherapy by Lapteva, Natalia, Huang, Xue F

“…To date cancer immunotherapy has only achieved limited clinical efficacy, thus more efficient immunotherapeutic approaches need to be explored. The CC…”
Get more information

Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs by Steffin, David H M, Muhsen, Ibrahim N, Hill, LaQuisa C, Ramos, Carlos A, Ahmed, Nabil, Hegde, Meenakshi, Wang, Tao, Wu, Mengfen, Gottschalk, Stephen, Whittle, Sarah B, Lulla, Premal D, Mamonkin, Maksim, Omer, Bilal, Rouce, Rayne H, Heczey, Andras, Metelitsa, Leonid S, Grilley, Bambi J, Robertson, Catherine, Torrano, Virginia, Lapteva, Natalia, Gee, Adrian P, Rooney, Cliona M, Brenner, Malcolm K, Heslop, Helen E

“…Subsequent malignancies are well-documented complications in long-term follow-up of cancer patients. Recently, genetically modified immune effector (IE) cells…”
Get full text